TABLE OF CONTENT: 1. Introduction 1.1. Research Scope 1.2. Market Segmentation 1.3. Research Methodology 1.4. Definitions and Assumptions 2. Executive Summary 3. Market Dynamics 3.1. Market Drivers 3.2. Market Restraints 3.3. Market Opportunities 4. Key Insights 4.1. Overview of the Number of Botulinum Toxin Injection Procedures by Key Countries 4.2. Overview of the Regulatory Scenario by Key Countries 4.3. Pricing Analysis 4.4. Overview of the Types of Botulinum Toxins 4.5. Pipeline Analysis 4.6. Overview of New Product Launches 4.7. Overview of Applications of Botulinum Toxin in Therapeutics and Recent Regulatory Approvals 4.8. Overview of the Reimbursement Scenario by Key Countries 5. Global Botulinum Toxin Market Analysis, Insights and Forecast, 2015-2026 5.1. Key Findings / Summary 5.2. Market Analysis, Insights and Forecast – By Application 5.2.1.Therapeutics 5.2.1.1. Chronic Migraine 5.2.1.2. Spasticity 5.2.1.3. Overactive Bladder 5.2.1.4. Cervical Dystonia 5.2.1.5. Blepharospasm 5.2.1.6. Others 5.2.2. Aesthetics 5.3. Market Analysis, Insights and Forecast – By End User 5.3.1. Specialty & Dermatology Clinics 5.3.2. Hospitals & Clinics 5.3.3. Others 5.4. Market Analysis, Insights and Forecast – By Type 5.4.1. Botulinum Toxin Type A 5.4.2. Botulinum Toxin Type B 5.5. Market Analysis, Insights and Forecast – By Region 5.5.1. North America 5.5.2. Europe 5.5.3. Asia Pacific 5.5.4. Latin America 5.5.5. Middle East & Africa 6. North America Botulinum Toxin Market Analysis, Insights and Forecast, 2015-2026 6.1. Key Findings / Summary 6.2. Market Analysis – By Application 6.2.1. Therapeutics 6.2.1.1. Chronic Migraine 6.2.1.2. Spasticity 6.2.1.3. Overactive Bladder 6.2.1.4. Cervical Dystonia 6.2.1.5. Blepharospasm 6.2.1.6. Others 6.2.2. Aesthetics 6.3. Market Analysis – By End User 6.3.1. Specialty & Dermatology Clinics 6.3.2. Hospitals & Clinics 6.3.3. Others 6.4. Market Analysis – By Type 6.4.1. Botulinum Toxin Type A 6.4.2. Botulinum Toxin Type B 6.5. Market Analysis – By Country 6.5.1. U.S. 6.5.2. Canada 7. Europe Botulinum Toxin Market Analysis, Insights and Forecast, 2015-2026 7.1. Key Findings / Summary 7.2. Market Analysis – By Application 7.2.1. Therapeutics 7.2.1.1. Chronic Migraine 7.2.1.2. Spasticity 7.2.1.3. Overactive Bladder 7.2.1.4. Cervical Dystonia 7.2.1.5. Blepharospasm 7.2.1.6. Others 7.2.2. Aesthetics 7.3. Market Analysis – By End User 7.3.1. Specialty & Dermatology Clinics 7.3.2. Hospitals & Clinics 7.3.3. Others 7.4. Market Analysis – By Type 7.4.1. Botulinum Toxin Type A 7.4.2. Botulinum Toxin Type B 7.5. Market Analysis – By Country/ Sub-Region 7.5.1. U.K. 7.5.2. Germany 7.5.3. France 7.5.4. Spain 7.5.5. Italy 7.5.6. Scandinavia 7.5.7. Rest of Europe 8. Asia Pacific Botulinum Toxin Market Analysis, Insights and Forecast, 2015-2026 8.1. Key Findings / Summary 8.2. Market Analysis – By Application 8.2.1. Therapeutics 8.2.1.1. Chronic Migraine 8.2.1.2. Spasticity 8.2.1.3. Overactive Bladder 8.2.1.4. Cervical Dystonia 8.2.1.5. Blepharospasm 8.2.1.6. Others 8.2.2. Aesthetics 8.3. Market Analysis – By End User 8.3.1. Specialty & Dermatology Clinics 8.3.2. Hospitals & Clinics 8.3.3. Others 8.4. Market Analysis – By Type 8.4.1. Botulinum Toxin Type A 8.4.2. Botulinum Toxin Type B 8.5. Market Analysis – By Country/ Sub-Region 8.5.1. Japan 8.5.2. China 8.5.3. India 8.5.4. Australia 8.5.5. Southeast Asia 8.5.6. Rest of Asia Pacific 9. Latin America Botulinum Toxin Market Analysis, Insights and Forecast, 2015-2026 9.1. Key Findings / Summary 9.2. Market Analysis – By Application 9.2.1. Therapeutics 9.2.1.1. Chronic Migraine 9.2.1.2. Spasticity 9.2.1.3. Overactive Bladder 9.2.1.4. Cervical Dystonia 9.2.1.5. Blepharospasm 9.2.1.6.Others 9.2.2. Aesthetics 9.3. Market Analysis – By End User 9.3.1.Specialty & Dermatology Clinics 9.3.2. Hospitals & Clinics 9.3.3. Others 9.4. Market Analysis – By Type 9.4.1. Botulinum Toxin Type A 9.4.2. Botulinum Toxin Type B 9.5. Market Analysis – By Country/ Sub-Region 9.5.1. Brazil 9.5.2. Mexico 9.5.3. Rest of Latin America 10. Middle East & Africa Botulinum Toxin Market Analysis, Insights and Forecast, 2015-2026 10.1. Key Findings / Summary 10.2. Market Analysis – By Application 10.2.1. Therapeutics 10.2.1.1. Chronic Migraine 10.2.1.2. Spasticity 10.2.1.3. Overactive Bladder 10.2.1.4. Cervical Dystonia 10.2.1.5. Blepharospasm 10.2.1.6.Others 10.2.2. Aesthetics 10.3. Market Analysis – By End User 10.3.1. Specialty & Dermatology Clinics 10.3.2. Hospitals & Clinics 10.3.3. Others 10.4. Market Analysis – By Type 10.4.1. Botulinum Toxin Type A 10.4.2. Botulinum Toxin Type B 10.5. Market Analysis – By Country/ Sub-Region 10.5.1. GCC Countries 10.5.2. South Africa 10.5.3. Rest of Middle East & Africa 11. Competitive Analysis 11.1. Key Industry Developments 11.2. Global Market Share Analysis (2018) 11.3. Competition Dashboard 11.4. Comparative Analysis – Major Players 11.5. Company Profiles (Overview, Products & Services, SWOT Analysis, Recent Developments, Strategies, Financials (Based on Availability)) 11.5.1. ALLERGAN 11.5.2. Ipsen Pharma 11.5.3. Merz Pharma 11.5.4. Medytox 11.5.5. US WorldMeds, LLC (Solstice Neurosciences, LLC) 11.5.6. Galderma laboratories 11.5.7. Lanzhou Institute of Biological Products Co., Ltd. 11.5.8. Revance Therapeutics, Inc. 12. Strategic Recommendations

ALLERGAN Ipsen Pharma Merz Pharma Medytox US WorldMeds, LLC (Solstice Neurosciences, LLC) Galderma laboratories Lanzhou Institute of Biological Products Co., Ltd. Revance Therapeutics, Inc.